A carregar...
T790M mutant copy number quantified via ddPCR predicts outcome after osimertinib treatment in lung cancer
Osimertinib prolongs progression-free survival (PFS) in patients with metastatic, epidermal growth factor receptor (EGFR) T790M-mutated, non-small cell lung cancer (NSCLC) after failure of EGFR tyrosine kinase inhibitor (TKI) therapy. We investigated the utility of T790M mutant copy number quantific...
Na minha lista:
| Publicado no: | Oncotarget |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals LLC
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6021335/ https://ncbi.nlm.nih.gov/pubmed/29963252 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.25332 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|